DHR Research Update — August 28, 2026 (Updated)
Updated Thesis
Danaher is a diversified life-sciences, biotechnology and diagnostics company whose Danaher Business System, installed instrument base, recurring consumables and service revenue, regulatory and application know-how, and portfolio of specialized brands support high business quality. Q2 2026 revenue was $6.265 billion, up 5.5% year over year in the most recent quarter, while earnings grew 56.8% year over year in the most recent quarter; TTM gross, operating and net margins were 58.5%, 20.4% and 15.9%, respectively. Growth is moderating rather than hypergrowth, with management guiding 2026 core revenue growth of 3.0% to 4.0%, but biotechnology order improvement, Life Sciences momentum, and acquired acute-care monitoring exposure provide potential upside.
The investment grade as of this refresh is A- — high business quality. A-tier business, A-tier valuation, with 42.8% upside to $286.52 fair value and identifiable CEO-transition and StatLab-closing catalysts.
Key Metrics at a Glance
- Revenue growth: +5.5% year over year
- Net margin: 15.9%
- Fair value upside: +42.8% to our estimate of $287
Current price: $200.58
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. Danaher Corporation remains in our covered universe with a high-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full DHR research →](/stocks/DHR)